USC scientists have surmounted a big roadblock in regenerative medicine that has so far constrained the ability to use repurposed cells to treat diseases. The researchers figured out how to reprogram ...
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif., August 25, 2025--(BUSINESS WIRE)--Aditxt ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on ...
By combining DNA instructions with our proprietary delivery platform, we are aiming for digital-like precision in how the immune system is retrained. With the first ADI product candidate ADI-100, we ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...
In our cells, our DNA carries chemical or 'epigenetic' marks that decide how genes will be used in different tissues. Yet in the group of specialised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results